Showing 1 - 20 results of 21,342 for search '(( ((significant sizes) OR (significant benefits)) decrease ) OR ( significant decrease decrease ))', query time: 0.58s Refine Results
  1. 1
  2. 2

    Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

    Published 2025
    “…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
  3. 3
  4. 4
  5. 5

    Supplementary Material for: Longitudinal Decrease in Left Ventricular Size with Age: Impact on Mortality and Cardiovascular Hospitalization by figshare admin karger (2628495)

    Published 2025
    “…The prognostic significance of reductions in LV size in hearts with normal baseline LV size remains unclear. …”
  6. 6
  7. 7
  8. 8
  9. 9

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
  10. 10

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
  11. 11

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
  12. 12
  13. 13
  14. 14
  15. 15

    Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. by Francesca Catto (21253435)

    Published 2025
    “…However, there is only a minimal effect on decreasing plaque size. (C) Short-term-treatment with a high dose of netoglitazone reveals a significant reduction in plaque size, especially observed in the hippocampus, striatum, thalamus, hypothalamus, midbrain, and hindbrain. …”
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20